U.S. FDA approves Merck’s Vaxneuvance (pneumococcal 15 valent conjugate vaccine) for the prevention of invasive pneumococcal disease in infants and children


22 June 2022 - Clinical data supporting approval demonstrated non-inferior immune responses for all serotypes shared with PCV13 following a four dose series and superior immune responses for important disease causing shared serotype 3 and unique serotypes 22F and 33F compared to PCV13.

Merck announced today that the U.S. FDA has approved an expanded indication for Vaxneuvance (pneumococcal 15 valent conjugate vaccine) to include children 6 weeks through 17 years of age.

Read Merck press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Outcome , US , Vaccine , Paediatrics